Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment

被引:1
|
作者
Nguyen, William Q. [1 ]
Chrisman, Lauren P. [1 ]
Enriquez, Gail L. [2 ]
Hooper, Madeline J. [1 ]
Griffin, Teresa L. [1 ]
Ahmad, Merjaan [2 ]
Rahman, Sophia [2 ]
Green, Stefan J. [3 ]
Seed, Patrick C. [4 ,5 ]
Guitart, Joan [1 ]
Burns, Michael B. [2 ]
Zhou, Xiaolong A. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA
[2] Loyola Univ Chicago, Dept Biol, Chicago, IL USA
[3] Rush Univ, Genom & Microbiome Core Facil, Med Ctr, Chicago, IL USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Infect Dis, Chicago, IL USA
[5] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 14卷
关键词
cutaneous T cell lymphoma; microbiome; phototherapy; gut dysbiosis; cancer; lymphoma; skin cancer; inositol; MYCOSIS-FUNGOIDES; SKIN MICROBIOME; PATHOGENESIS; DIVERSITY; BACTERIA; PROTEINS; BUTYRATE; 16S;
D O I
10.3389/fimmu.2023.1280205
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent studies have shown a close relationship between cutaneous T-cell lymphoma (CTCL) and its microbiome. CTCL disease progression is associated with gut dysbiosis and alterations in bacterial taxa parallel those observed in immunologically similar atopic dermatitis. Moreover, the microbial profile of lesional skin may predict response to narrowband ultraviolet B (nbUVB), a common skin-directed therapy. However, the relationship between the gut microbiome, an immunologically vital niche, and nbUVB remains unexplored in CTCL. Herein, we performed 16S rRNA sequencing and PICRUSt2 predictive metagenomics on DNA extracted from stool swabs of 13 CTCL patients treated with nbUVB, 8 non-treated patients, and 13 healthy controls. Disease response was assessed with modified Severity Weighted Assessment Tool (mSWAT); of nbUVB-treated patients, 6 improved (decreased mSWAT), 2 remained stable, and 5 worsened (increased mSWAT). Protective commensal bacteria including Lactobacillaceae and Erysipelatoclostridiaceae were significantly less abundant in CTCL patients compared to controls. With treatment, the CTCL gut microbiome exhibited decreased phylogenetic diversity and lower relative abundance of pro-inflammatory Sutterellaceae. Sutterellaceae was also significantly more abundant in patients who worsened, and Eggerthellaceae and Erysipelotrichaceae trended higher in patients who improved. Finally, PICRUSt2 functional predictions based on shifts in abundance of bacterial sequences repeatedly identified alterations in inositol degradation, which plays a key role in host immunomodulation, including inositol phospholipid signaling relevant to T-cell survival and proliferation. Our results bolster the paradigm of gut dysbiosis in CTCL and its functional implications in disease pathogenesis, and further delineate bacterial taxa associated with nbUVB response and with nbUVB treatment itself.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] REVIEW OF IMMUNOMODULATION BY PHOTOPHERESIS - TREATMENT OF CUTANEOUS T-CELL LYMPHOMA, AUTOIMMUNE-DISEASE, AND ALLOGRAFT-REJECTION
    WOLFE, JT
    LESSIN, SR
    SINGH, AH
    ROOK, AH
    ARTIFICIAL ORGANS, 1994, 18 (12) : 888 - 897
  • [42] Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis
    Miyagaki, T.
    Sugaya, M.
    Suga, H.
    Ohmatsu, H.
    Fujita, H.
    Asano, Y.
    Tada, Y.
    Kadono, T.
    Sato, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (01) : e60 - e67
  • [43] The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma
    Lin, Zhouning
    Mao, Dan
    Jin, Changyu
    Wang, Jiaping
    Lai, Yanli
    Zhang, Yanli
    Zhou, Miao
    Ge, Qunfang
    Zhang, Ping
    Sun, Yongcheng
    Xu, Kaihong
    Wang, Yi
    Zhu, Huiling
    Lai, Binbin
    Wu, Hao
    Mu, Qitian
    Ouyang, Guifang
    Sheng, Lixia
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy
    Quiros, PA
    Kacinski, BM
    Wilson, LD
    CANCER, 1996, 77 (09) : 1912 - 1917
  • [45] CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment
    Sakamoto, Yuma
    Ishida, Takashi
    Masaki, Ayako
    Murase, Takayuki
    Ohtsuka, Eiichi
    Takeshita, Morishige
    Muto, Reiji
    Iwasaki, Hiromi
    Ito, Asahi
    Kusumoto, Shigeru
    Nakano, Nobuaki
    Tokunaga, Masahito
    Yonekura, Kentaro
    Tashiro, Yukie
    Iida, Shinsuke
    Utsunomiya, Atae
    Ueda, Ryuzo
    Inagaki, Hiroshi
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 876 - 884
  • [46] Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
    Quiros, PA
    Jones, GW
    Kacinski, BM
    Braverman, IM
    Heald, PW
    Edelson, RL
    Wilson, LD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (05): : 1027 - 1035
  • [47] Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients
    Bladon, J
    Taylor, PC
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (04) : 707 - 711
  • [48] Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease
    Angelov, Daniel
    Dillon, James
    Mellerick, Lisa
    Pender, Emily
    Bacon, Larry
    Lee, Greg
    Higgins, Liz
    McCarty, Heather
    Gillham, Charles
    Quinn, John
    O'Gorman, Susan
    Leonard, Niamh
    McMenamin, Mairin
    Vandenberghe, Elisabeth
    BONE MARROW TRANSPLANTATION, 2022, 57 (08) : 1332 - 1334
  • [49] Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma
    Fierro, M
    Doveil, GC
    Quaglino, P
    Savoia, P
    Verrone, A
    Bernengo, MG
    DERMATOLOGY, 1997, 194 (03) : 268 - 272
  • [50] Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma
    Rejeski, Kai
    Jain, Michael D.
    Smith, Eric L.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (07): : 418 - 428